drugset / Trial / NCT05523609

Vitamin D and Calcium Supplementation in Breast Cancer

NCT05523609

Phase 2/3 Unknown 40 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims at assessing the vitamin Dstatus in breast cancer patients who receive letrozole for more than two months and to evaluate effects of vitamin D3 and calcium supplementation on arthalgia caused by letrozole on these patients.

Timeline

Start
2022-11-01
Primary completion
2024-09
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium carbonate Other / unclassified 1000 mg
Subject Cholecalciferol Other / unclassified 2000 iu
Background Letrozole Other / unclassified 2.5 mg

Indications